Fåhraeus Startup and Growth

Fåhraeus Startup and Growth AB (FSG) is an active Nordic venture capital firm specializing in early-stage investments within the life sciences and technology sectors. The firm provides capital and hands-on strategic support to startups developing innovative solutions in diagnostics, pharma/biotech R&D tools/platforms, medical devices, digital health/AI for healthcare delivery. Its current fund has invested in at least six startups since mid–2023 across the Nordics. Portfolio highlights include Aplagon’s APAC program for thrombo-inflammatory diseases now entering Phase 2a clinical trials.

As an investor rather than a drug developer or biotech operator itself, it does not have its own clinical results but supports companies with promising early-stage data.

The team combines operational experience from serial entrepreneurship with deep investment expertise. Key people include Christer Fåhraeus (Founder/General Partner), Linus Wiebe (Managing Director/General Partner), Johanna Asklin (General Partner), Emanuel Stihl and Alexander Jöndell.